Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
double recombinant vaccinia virus VV-GMCSF-Lact
- Development stage
- Phase 1
- Lead developer
- Institute of Chemical Biology and Fundamental Medicine SB RAS and State Research Center of Virology and Biotechnology Vector
- Modality
- Recombinant Proteins and Enzymes, Oncolytic Viruses → Oncolytic Therapeutics
- Administration
- Intratumoral, Intravenous
01
Overview
double recombinant vaccinia virus VV-GMCSF-Lact is a genetically engineered oncolytic virus based on the Lister strain (L-IVP) of the vaccinia virus. It has deletions in the viral thymidine kinase and growth factor genes, with insertions of two therapeutic genes: human granulocyte-macrophage colony-stimulating factor (GM-CSF) and lactaptin, an apoptosis-inducing protein derived from human milk kappa-casein. GM-CSF stimulates antitumor immune responses by recruiting granulocytes, macrophages, and promoting dendritic cell differentiation. Lactaptin induces apoptosis in cancer cells via the mitochondrial pathway. The drug is designed for intratumoral or intravenous administration to treat solid tumors such as glioma and metastatic breast cancer, showing high cytotoxic activity against chemoresistant tumor models[2][5][6].
- Brand names
- Oncostar
- Other names
- double recombinant vaccinia virus VV-GMCSF-Lactrecombinant vaccinia virus VV-GMCSF-Lact
02
Targets
CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)
Beyond the preview
Go deeper on double recombinant vaccinia virus VV-GMCSF-Lact.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on double recombinant vaccinia virus VV-GMCSF-Lact.